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Summary Most randomised clinical trials of cancer treatment include a few hundred patients or less. Recent
statistical papers advocate that sometimes thousands of patients should be entered. In this paper I show that
for certain types of cancer trials the 'thousands policy' is not required while for others it is desirable but not
feasible. In the latter case other strategies should be considered, such as two-stage phase III studies or parallel
studies leading to overviews. There is, however, an important subset of trials for which application of the
thousands policy is both necessary and feasible. The key to progress lies partly in the achievement of greater
recruitment rates in trials of common cancers and partly in greater inter-group collaboration.
The past 20 years have seen a rapid increase in the number
of clinical trials designed to evaluate treatments for cancer.
The role of medical statisticians in the design of these trials
has been central, particularly in phase III studies, where the
concept of randomised allocation of treatments is now
recognised as a fundamental principle. Although the debate
between proponents of randomisation and those who favour
methodology using historical controls or clinical data bases
lingers, there is now emerging an important and perhaps
more pressing controversy - that of the number of patients
required in a randomised clinical trial.
In all but a few exceptions (e.g. Byar, 1973; Cancer
Research Campaign Working Party, 1980; Nolvadex Adju-
vant Trial Organization, 1985; Riley et al., 1986) randomised
clinical trials in cancer have, until now, included several
hundreds of patients or less. On the other hand, a strong
school of opinion has emerged which advocates that some-
times thousands of patients, rather than hundreds, should be
entered into randomised trials (Yusuf et al., 1984). The
notion of such a quantum leap in the desired size arouses
much emotion among investigators, both because it casts
aspersions on the value of previous and current trials and
because of the perceived difficulty of achieving such large
sizes in the future. As a consequence the debate has gener-
ated much heat.
In this paper I attempt to clarify the statistical arguments
behind the 'thousands of patients' policy and then highlight
the areas of cancer research to which these arguments apply
and to which they do not. I will show that for certain types
of cancer research, the 'thousands' policy is not required,
and for other types it is desirable but not feasible. This will
raise the question of what to do in such circumstances.
Finally I will point out the type of cancer research where the
'thousands' policy is both desirable and feasible.
The statistical argument for entering very large numbers of
patients
The results of a randomised clinical trial are evaluated by
statistical comparison of the outcome of groups of patients
allocated one of two (or more) treatment options. The
outcome of treatment is quite often multifaceted. For exam-
ple, in a trial of adjuvant treatment for breast cancer one may
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be interested in the time to local recurrence, metastatic
spread and death, as well as acute and chronic toxicity from
the treatment. For the purpose of planning the sample size
of the study it is usually possible to identify a single major
end-point, which is used to summarise treatment outcome.
This is often chosen to be time to death or time to first
recurrence of disease; in the following discussion we assume
that such an end-point is appropriate.
The number of patients required in the study is calculated
with respect to the selected major end-point. Specifically, the
number of patients is chosen so as to guarantee a high
probability (usually 90%) of detecting a statistically signifi-
cant difference (usually at 5% level) on the condition that a
certain difference, 6, actually exists. If the true difference is
greater than 6 then the chance of showing a significant
difference will be greater than 90%. Conversely, if the true
difference is smaller than 6 then the trial will have a less
than 90% chance of showing significance; indeed the chances
of showing significance are reduced quite dramatically if the
true difference is considerably less than 6. Table I displays
this phenomenon more precisely: if the difference is half that
specified, then the chances of detecting it as significant drop
from 90 to 37%. For this reason the choice of 6 is quite
crucial in the planning of sample size, and its value should
represent a treatment difference that can realistically be
expected. Of course the choice of 6 is partly a subjective
matter, but there is now a long experience of past attempts
to improve the therapy of cancer, showing that in almost all
cases the margin of benefit was either not apparent or of
moderate size. Large improvements, such as have resulted
from chemotherapy for testicular teratoma, have been extre-
mely rare. For this reason it is usually unrealistic to set 6 at
a level that would represent a large improvement. For
example, it would be unrealistic to plan trials of adjuvant
Table I Chance (%) of demonstrating a significant treatment
difference (5% level) in a trial planned to have a 90% chance
ofdetecting a difference 60, when the true difference is really 6
Assumed difference (60)
True difference (b) 10% 15% 20% 25%
5% 37 19 13 10
10% 90 58 37 25
155% 90 68 50
20% 90 73
25% 90
The assumption is that the end-point is a surival rate,
which is 50% for the control group; however, the numbers
here remain essentially unchanged for survival rates between
15 and 85%.
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therapy in rectal cancer to detect increases in the 5-year
survival rate from the current 35% to 55%. Adjuvant
treatments available, such as radiotherapy, cannot be
expected to increase the absolute survival rate by more than
5-10% (i.e. to 40-45%). As shown in Table I, trials based
on detecting a 20% increase are likely to fail to detect a
difference half this size. Nevertheless, a 10% increase in 5-
year survival, or even a 5% increase, would be clinically
worthwhile, especially in a common disease such as rectal
cancer.
Planning for moderate and more realistic treatment differ-
ences has a marked effect on the number of patients to be
entered in the study. Statistics has its own version of the
inverse-square law: to detect a difference a fractionfsmaller,
you need 1/f2 as many patients. For example, to detect half
the difference you need four times the number of patients.
Figure 1 shows the number of patients required for reliable
detection of a given treatment difference 6. In this figure, it
is assumed that the control treatment has a survival rate of
50%, rather typical of the 5-year rate for diseases such as
colonic cancer or rectal cancer. The figure shows that for
detection of improvements of 10%, the number of patients
required is about 1,000, and this number rises very rapidly as
the target difference becomes smaller. This is the basis of the
statistical argument for entering a thousand or more
patients. It should be noted that the required numbers are of
the same order as those shown in Figure 1 as long as the
control group's survival rate is between 20 and 80%. Outside
this range the required numbers become smaller. This point
will be elaborated later.
Requirements for very large trials
In an article entitled 'Why do we need some large and simple
randomized trials', Yusuf et al. (1984) clearly set out the
philosophy and requirements for such studies. Five necessary
conditions are described:
1. The question posed by the trial must be clinically
important.
2. The disease must be common.
3. The treatments must be widely applicable (i.e. able to
be used in most hospitals).
Difference in survival rates (%)
Figure 1 Number of patients (deaths) required to give a 90%
chance ofshowing a significant (5%) improvement (control survival
rate =5%).
4. The end-point should be simple to measure and the
entry protocol should be simple.
5. Only a modest treatment difference should be expected.
We have already discussed Item 5.
Items 1-3 are interrelated. A question might be considered
clinically important without necessarily addressing a
common disease or widely applicable treatments. However,
both these aspects will naturally enhance the question's
importance and its relevance to the wider clinical profession.
Moreover, there is a need for the question to be seen as
important, so that clinicians are encouraged to participate.
In addition, if the treatments are widely available, then there
will be opportunity for a greater range of clinical participa-
tion. Similarly, the more common the disease the greater the
number of potential entrants to the study.
Item 4 refers to the simplicity of the study procedures. To
encourage participation the study should be designed to fit
as unobtrusively as possible into normal clinical practice.
Collection of data should usually be restricted to the mini-
mum required to answer the main questions posed. These
authors are implicitly critical of current cancer trials, most of
which enter a few hundreds of patients. The next section
examines which types of randomised cancer clinical trials do
not require the very large numbers that have been
advocated.
Trials for which we do not always need very large numbers
(1,000 or more)
It was argued above that large numbers are required when:
(a) the treatment outcome is summarised by the time to an
adverse event and (b) the expected treatment difference, 6, is
at best moderate.
Most cancer trials are based on the analysis of time to an
adverse event. The most common alternative end-point is the
response or non-response of manifest disease to a therapy.
The argument regarding the numbers of patients is not
substantially altered by the use of tumour response as an
end-point. There is, however, a class of trials where a more
precise measure of treatment effect may be used. Superficial
bladder cancer may be removed by localised procedures such
as surgery, intravesical chemotherapy or a combination.
Patients with this disease tend to have recurrences of their
tumours which are again superficial and which may be
repeatedly eradicated by local treatment. The response to the
initial procedure may thus be measured by the subsequent
rate of recurrences in the patient, a more sensitive measure
of treatment effect than the occurrence or non-occurrence of
a single event. Using such an end-point one would expect to
be able to detect treatment differences with hundreds rather
than thousands of patients. This has indeed been verified by
recently published results (Denis et al., 1987; Tolley et al.,
1988).
It was argued before that in clinical trials it is usual that
the expected improvement from a new treatment is realisti-
cally only moderate. There are exceptions. For example,
several uncontrolled studies of adjuvant chemotherapy for
osteosarcoma (Jaffe et al., 1974; Cortes et al., 1974; Eilber et
al., 1978; Rosen et al., 1981) had suggested a large improve-
ment in relapse-free rate. When a randomised study to test
this hypothesis was conducted (Link et al., 1986) it was
reasonable to plan to enter a few hundred patients. In fact,
the discovery of a large treatment difference led to early
termination of this study.
One further aspect needs to be considered, namely the rate
at which the adverse event will occur. The statistical argu-
ment above is somewhat simplified. The determining factor
for the ability of a trial to detect a given treatment difference
is not actually the number of patients, but the number of
events. For example, suppose the end-point is time to death;
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to detect a given treatment difference with equal reliability as
a trial with 2,000 patients but the same number of deaths,
500. Figure 1 shows that about 500 deaths will reliably
detect a difference of 10% in survival rates. If P is the
proportion of deaths observed among patients in the trial,
then the number of patients required will be 500/P. Figure 1
illustrates the case where P is approximately 0.5, when about
1,000 patents will be needed. However, for diseases where P
is close to I a trial size of around 500 will be sufficient to
detect a moderate treatment difference.
A high mortality rate also has consequences for the
desired expected treatment difference, 6. Suppose a disease
has a median survival time of only 6 months. If the death
rate is constant throughout the first 2 years after treatment
then by 2 years there will be approximately 5% of survivors.
One needs to ask not only what is the expected improve-
ment, 6, from a new treatment, but also what is the smallest
clinically worthwhile improvement. This latter quantity will
depend on the relative toxicity of the new treatment, the
relative inconvenience to the patient or other factors. It is
quite likely that increasing the median survival by less than 3
months would be seen as insufficient to justify routine use of
the new treatment. Trials should not usually be conducted
unless the expected improvement from the new treatment is
at least equal to the smallest clinically worthwhile improve-
ment. In diseases with high mortality this will often be at
least 50% increase in the median survival time. This trans-
lates into an increase in survival rate from about 5% to 14%
at 2 years. As mentioned above, this improvement can be
detected without very large numbers, since the control
group's survival rate is less than 20%. In fact the 9%
improvement is a large relative increase and requires only a
few hundred patients to detect. It is a moot point whether
treatments which can realistically be expected to produce
such benefits are always chosen for study, and one could
argue that there are far too many studies of therapies which
give little chance of such a major improvement; but by
conducting a trial with a few hundred patients we, at least,
do not risk missing a clinically important difference because
of too small a trial. There are several common cancers that
have a high mortality rate (Table II). The above arguments
support the use of moderate-size trials in these diseases.
Trials which need to be large but cannot be
Although the considerations of the previous section exempt a
substantial proportion of cancer clinical trials from needing
large numbers of patients, there remains probably more than
half of the current randomised phase III studies which are
not exempted. Nevertheless, if we consider the requirements
for a successful large trial, we find many barriers to the
'large trial' approach.
Rare diseases
There is no accepted definition of a 'rare' disease. For the
purposes of this discussion I use a cut-off point of less than
2,000 new cases per annum in England and Wales. A list of
some such cancers where clinical trials are currently of
interest is given by Table III. To enter 1,000 or more
Table II Cancers with a high mortality rate for which
moderate-size trials may have statistical justification
Site Qualification
Lung Small cell
Non-operable non-small cell
Stomach Non-operable
Pancreas
Oesophagus
Ovary Locally advanced
Brain Astrocytoma, grades 3 and 4
Table III Examples of rare cancers or subgroups of cancers for
which very large national trials are not currently feasible
Site Qualification
Mouth Locally advanced, squamous cell carcinoma
Pharynx Locally advanced, squamous cell carcinoma
Liver
Gall bladder
Anus Squamous cell carcinoma
Larynx
Bone Sarcoma
Cervix Locally advanced
Testis
Eye
Soft tissue Sarcoma
Lymphatics Hodgkin's disease
patients into a national trial would require entry of most of
the newly diagnosed patients. While high proportions of
entry can be achieved where patients are usually referred to
specialist centers (e.g. acute myeloid leukaemia and osteo-
sarcoma) it must be recognised that, where a wide distribu-
tion of general surgeons or physicians treats the patients, the
proportion of entry to the trials is currently below 10% and
mostly in the range 0-4% (Tate et al., 1978). It is unlikely
that this proportion could be raised quickly to 50% or more,
so very large trials in these rare diseases are probably not
feasible, at least at the national level. Attempts to overcome
the problems in rare disease have been made by running
international collaborative trials (e.g. European Osteosar-
coma Intergroup, 1986; Medical Research Council, 1987).
These efforts are quite difficult to organise and it is too early
to assess their achievements.
Treatments which can be given only in specialist centres
Many interesting developments in cancer treatment require
unusual technical expertise, special equipment or some other
resource which is not widely available. Clearly large ran-
domised trials of such treatments are impossible because the
number of patients who can be given the treatment is limited
by the capacity of the few clinics who will administer it.
There have been many examples of such treatments, includ-
ing high energy particle radiotherapy (for example neutron
radiotherapy), hyperbaric oxygen in conjunction with radio-
therapy, bone marrow transplantation, hyperthermia and
photodynamic therapy. Chemotherapy regimens that are
particularly complex or toxic may also be included in this
list.
An important distinction to be made in these cases is
between (a) those treatments which are in an early stage of
development but which are likely, with further development
or with appropriate training of staff in other clinics, to
become more widely available, and (b) those treatments
which are not likely to become generally available to cancer
patients. The latter do not deserve the costly full scale
evaluation of a randomised phase III trial. For an example
of correspondence regarding such a treatment see Baum
(1987).
Treatments which eventually could, if shown to be worth-
while, become widely available, are genuine candidates for
randomised comparisons but there may need to be an
alternative strategy to the very large study. Two possible
strategies are outlined below.
Two-stage phase III studies
One way to address the problems described above is to
divide phase III studies into two stages (Ellenberg &
Eisenberger, 1985). In the first stage a moderate number of
patients (a few hundred) are entered and the results eva-
luated. Should the results reveal a trend towards benefit
(without necessarily reaching statistical significance) further
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might be made and a very much larger study (the second
stage) then conducted. This resembles what sometimes hap-
pens in practice, except that the moderate-size stage is
initially planned as the definitive study. Consequently, there
is an unwillingness to continue investigation of the treat-
ment, and also too strong an emphasis on the statistical
significance of the result. A possible weakness in this two-
stage strategy is the added length of time it may take to
complete the full phase III programme, due to the need to
assess the results of the first stage before deciding whether to
proceed to the very large trial.
Parallel studies (leading to overviews)
A second strategy is to accept that one's own individual
study will, by itself, probably not provide a definitive
evaluation of the therapy, but to design the trial in conjunc-
tion with other groups of investigators who are studying the
identical (or nearly identical) question. The idea is that the
study should form one of a series of parallel studies, and
that the results from these studies should be combined at
some future date to achieve the necessary precision to detect
any moderate but clinically worthwhile improvement. One's
own study, to contribute substantially to the overview,
should constitute an appreciable fraction (> 10%) of the few
thousand patients who may eventually be required. The
methodology for combining the results of parallel studies
(known as 'overview') has been well described (Peto, 1987;
Antiplatelet Triallists' Collaboration, 1988; Early Breast
Cancer Triallists' Collaborative Group, 1988). This strategy
carries some logistic advantages over the large international
trial, being simple and more flexible to organise and execute.
A weakness is that the success of one's own strategy lies
partly outside one's own influence, being dependent on the
successful completion of at least some of the other parallel
studies.
A potential problem, introduced by the concept of parallel
studies and overview analysis, is the apparent license which
this gives to investigators who wish to conduct their own
small study at their local centre. This could eventually lead
to the dismantling of collaborative groups and increased
fragmentation of clinical research. This tendency should be
opposed; the parallel study concept should be used as a
progression towards a flexible form of inter-group collabor-
ation rather than as a method of rescuing information from
the debris of a very large number of poorly planned local
studies with small numbers of patients.
Trials which could and should be large
The requirements for large randomised trials can apply to
several areas of cancer clinical research. There are currently
some important questions relating to widely applicable treat-
ments for common cancers. In most cases there is already
some considerable experience with these treatments, and the
fact that their value is still doubtful argues that their benefits
are at best moderate. However, a moderate improvement in
the survival rate of a common cancer could mean the saving
of several hundred lives each year in the UK. Therefore
these treatments are worth further evaluation until even a
moderate benefit has been excluded, or preferably until a
moderate benefit has been established. Table IV is a list of
such questions identified at recent meetings of the European
Organization for Research into Treatment of Cancer
(EORTC), Medical Research Council (MRC) and United
Kingdom Coordinating Committee for Cancer Research
(UKCCCR). It is likely that with a simple protocol and
good management a collaborative group would be able to
enter 1,000 patients or more into trials to answer some of
these questions.
The concept of parallel studies is useful also for studying
these questions. First, although the benefit may be moderate
and detectable by any one large study, it may be required to
estimate its magnitude quite precisely so as to balance the
Table IV Some questions which may be suitably studied by very
large randomised trials
Site Question
Lung Adjuvant radiotherapy for operable
non-small cell
Colon/rectum Intra-hepatic 5FU
Rectum Adjuvant radiotherapy
Breast, under 50 years Adjuvant Tamoxifen
Adjuvant castration
Breast, over 50 years Duration of adjuvant Tamoxifen
CMF cytotoxic chemotherapy
Prostate Immediate versus deferred orchidectomy
Dose of diethylstilboestrol
benefit against any increase in short-term or long-term
toxicity. The larger the number of patients in the analysis the
more precise will be the estimate; overviews of parallel
studies will be helpful in this regard. Secondly there may be
sensible hypotheses regarding treatment effects which vary
between subgroups of patients. It requires very large
numbers of patients indeed to reliably test hypotheses of this
type; once again overviews may be able to provide infor-
mation where no one single study will be sufficient.
Conclusion
In the conclusion to their paper, Yusuf et al. (1984) wrote:
'The intent of this article is not to suggest that all trials
should be designed in one particular way, but merely to
stress the need for some very large, very simple trials of
widely practicable treatments.' This message has, unfortuna-
tely, on occasions been transformed into a universal plea for
larger trials in cancer research. It is correct to point out the
dearth of very large trials. This has resulted partly because,
when subdivided into anatomical site, histology and stage,
each individual cancer is not nearly as common as, say,
heart disease; partly because the treatments are generally
more complex; partly because of the failure of the statisti-
cians to become thoroughly involved in the substantive
aspects of the research, and thereby to provide informed
advice on what is a realistic expected treatment difference on
which to plan sample size; partly due to clinicians failing to
organise themselves so as to achieve large numbers of
patients, on the occasions when statisticians have advised so;
and partly due to over-complicated trial procedures. The
latter three failures can, under the impetus of the work by
Yusuf et al., be corrected, which should lead to some
improvements. However, as pointed out in this paper there
are areas of cancer clinical research, particularly in diseases
with high mortality, where thousands of patients are not
required in a trial. A radical change to present practice is
not indicated for these diseases. There are also, very often,
relatively rare conditions or complicated treatments which
cannot be studied with such large numbers. Sensible strate-
gies in these circumstances include a two-stage structure for
phase III trials, or inter-group collaboration in the form of
parallel studies.
Finally, there are many important questions in cancer
treatment which do indeed lend themselves to the very large
trial approach. Some of these are listed in this paper; no
doubt others can be identified or will emerge. Parallel studies
will also be useful for these questions. The key to progress
lies partly in the achievement of greater recruitment rates in
trials of common cancers and partly in greater inter-group
collaboration.
Although I take responsibility for the ideas expressed in this paper,
much was distilled from a meeting entitled, 'Cancer trial size: the
perfect, the practicable and the present', which was held in London
in March 1987, sponsored by the Medical Research Council and the
Cancer Research Campaign. I acknowledge in particular Richard
Peto and Rory Collins as well as many other speakers and
contributors from the floor. A written report of the meeting is to be
found in the British Journal of Cancer (Haybittle, 1988). I also
thank Professor R. Souhami, Dr M. Parmar and Dr J. Haybittle for
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